Vasopressin inhibits the adenylate cyclase activity of human platelet particulate fraction through V1-receptors

Arg⁸-vasopressin inhibited the adenylate cyclase activity of human platelet particulate fraction up to a maximum of 27% (IC₅₀ = 1.2 nM). This inhibition required the presence of 10 μM GTP and was optimal with 100 mM NaCl. Orn⁸-vasopressin had similar effects. 1-Deamino-Val⁴, D-Arg⁸-vasopressin did not by itself affect adenylate cyclase activity but competitively inhibited the action of Arg⁸-vasopressin (pA₂ = 7.74). Arg⁸-vasopressin did not inhibit adenylate cyclase in intact platelets but instead caused platelet aggregation, an effect that was also competitively inhibited by 1-deamino-Val⁴, D-Arg⁸-vasopressin (pA₂ = 7.82). Thus, platelets possess vasopressin receptors of the V₁ type that, under appropriate conditions, can mediate either inhibition of platelet adenylate cyclase or platelet aggregation.